WuXi AppTec Co Ltd - Company Profile

Powered by

All the data and insights you need on WuXi AppTec Co Ltd in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date WuXi AppTec Co Ltd Strategy Report

  • Understand WuXi AppTec Co Ltd position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

WuXi AppTec Co Ltd: Overview

Select Item

WuXi AppTec Co Ltd (Wuxi AppTec) is a pharmaceutical company that provides research and development and manufacturing services. The company offers services include chemistry drug CRDMO (contract research, development and manufacturing organization), biology discovery, preclinical testing and clinical research services and cell and gene therapies CTDMO (contract testing, development and manufacturing organization), small molecule, medical device testing, drug discovery, clinical research, oligonucleotide and peptide contract research and development. It provides its services to the pharmaceutical, biotech and medical device industries. The company operates in Asia-Pacific, Europe and North America. Wuxi AppTec is headquartered in Shanghai, China.

 Gain a 360-degree view of WuXi AppTec Co Ltd and make more informed decisions for your business Gain a 360-degree view of WuXi AppTec Co Ltd and make more informed decisions for your business Find out more
Headquarters China
Address 228 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, 200131
Website www.wuxiapptec.com.cn
Telephone 86 21 50461000
No of Employees 41,116
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange 603259 (SHA)
Revenue (2022) $5.7B 2.5% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 9% (2022 vs 2021)
Market Cap* $16.7B
Net Profit Margin (2022) XYZ 6.3% (2022 vs 2021)
* As of and is in US$
View WuXi AppTec Co Ltd financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

WuXi AppTec Co Ltd premium industry data and analytics

20+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for WuXi AppTec Co Ltd’s relevant decision makers and contact details.

20+

Catalyst Calendar

Proactively evaluate WuXi AppTec Co Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

19+

Clinical Trials

Determine WuXi AppTec Co Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

6

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

5

Pipeline Drugs

Identify which of WuXi AppTec Co Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

Products and Services

Services
Drug Research and Development and Medical Device Testing Services
Clinical Research Services
Small Molecule (CRDMO)
XYZ
XYZ
XYZ
Understand WuXi AppTec Co Ltd portfolio and identify potential areas for collaboration Understand WuXi AppTec Co Ltd portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Contracts/Agreements In February, WuXi Advanced Therapies received FDA approval for its Philadelphia site to manufacture AMTAGVI for Iovance.
2023 New Products/Services In April, the company added two 2,000 L reactors and a large-scale continuous purification system for peptide manufacturing at the Changzhou campus.
2023 Contracts/Agreements In January, WuXi STA entered into an agreement with Pasithea Therapeutics Corp to manufacture the active pharmaceutical ingredient (“API”) for Pasithea’s macrocyclic, next-generation MEK Inhibitor, PAS-004.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters WuXi AppTec Co Ltd Pharmaron Beijing Co Ltd Hangzhou Tigermed Consulting Co Ltd JOINN Laboratories China Co Ltd Shanghai ChemPartner Co Ltd
Headquarters China China China China China
City Shanghai Beijing Hangzhou Beijing Pudong
State/Province Shanghai Beijing Zhejiang Beijing Shanghai
No. of Employees 41,116 19,481 9,701 2,500 -
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Ge Li, PhD Chief Executive Officer; President; Chairman Executive Board 2017 57
Edward Hu Head - DDSU; Chief Executive Officer - WuXi ATU; Vice Chairman; Chief Investment Officer Executive Board 2020 62
Zhang Zhaohui Chief Operating Officer; Vice President; Director Executive Board 2017 55
Steve Qing Yang Director; Co-Chief Executive Officer Executive Board 2020 55
Minzhang Chen, PhD Director; Co- Chief Executive Officer Executive Board 2022 55
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into WuXi AppTec Co Ltd key executives to enhance your sales strategy Gain insight into WuXi AppTec Co Ltd key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer